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Summary 
Ensilication is a technology we developed that can physically stabilise proteins in silica 
without use of a pre-formed particle matrix1. Stabilisation is done by tailor fitting 
individual proteins with a silica coat using a modified sol-gel process2. 
Biopharmaceuticals, e.g. liquid-formulated vaccines with adjuvants, have poor thermal 
stability. Heating and/or freezing impairs their potency 3-5. As a result, there is an increase 
in the prevalence of vaccine-preventable diseases in low-income countries even when 
there are means to combat them 6-8. One of the root causes lies in the problematic vaccine 
‘cold-chain’ distribution3,4,9-12. We believe that ensilication can improve vaccine 
availability by enabling transportation without refrigeration. Here, we show that 
ensilication stabilises tetanus toxoid C fragment 13 (TTCF) and demonstrate that this 
material can be stored and transported at ambient temperature without compromising 
the immunogenic properties of TTCF in vivo. TTCF is a component of the diphtheria, 
tetanus and pertussis (DTP) vaccine. To further our understanding of the ensilication 
process, and its protective effect on proteins we have studied the formation of TTCF-silica 
nanoparticles via time-resolved Small Angle X-ray Scattering 14 (SAXS). Our results 
reveal ensilication to be a staged diffusion-limited cluster aggregation (DLCA) type 
reaction, induced by the presence of TTCF protein at neutral pH. Analysis of scattering 
data indicates tailor fitting of TTCF protein. The experimental in vivo immunisation data 
  
confirms the retention of immunogenicity after release from silica. Our results suggest 
that we could utilise this technology for multicomponent vaccines, therapeutics or other 
biopharmaceuticals that are not compatible with lyophilisation. 
Biopharmaceuticals are biologically derived active compounds directed for therapeutic or 
diagnostic usage. These can be identified as, for example, monoclonal antibodies, vaccines, 
cells and blood components. Many of these are proteins and not stable ex vivo. They must be 
stabilised to increase their shelf-life. The main approach in stabilisation of biopharmaceuticals 
is regulating temperature. Maintaining low (2-8 °C) temperatures retains native states of these 
compounds by lowering the kinetic energy. For many of the protein-based biopharmaceuticals, 
freezing is not beneficial as this weakens hydrophobic interactions, inherent in proteins, which 
may refold in a different conformation upon thawing. Within cold-chain transportation, from 
manufacturing to endpoint destination, temperature control has proven challenging. 
Fluctuations in temperature, heating/freezing3, can affect biopharmaceuticals resulting in 
aggregation, protein unfolding leading towards loss of potency. Our previous research 
describes a new alternative to stabilise biopharmaceuticals at ambient temperatures using sol-
gel technology 1. Sol-gel is based upon the polymerisation of a monomeric species that can 
undergo condensation with another monomer of its species 2. This eventually forms a particle 
as product which, in contact with other particles forms gels. There are many compounds that 
are compatible with this system, however our method uses a silica precursor, tetraethyl 
orthosilicate (TEOS). Hydrolysis of TEOS results in orthosilicic acid 15,16. This is a central Si 
atom bound with four hydroxyl (OH-) groups in a tetrahedral conformation and allows for rapid 
polymerisation under optimised conditions. The benefit here is the negative charge of silicic 
acid which we employ via electrostatics to direct it towards the positively charged biologically 
active component. Therefore, we can coat silica around a biologically active compound. The 
protein loaded silica powder obtained is resilient against fluctuations in temperature. TTCF is 
a ~52 kilodalton (kDa) fragment of the full tetanus neurotoxin and is a potent immunogenic 
protein. The DTP vaccine, which includes TTCF, has been shown to be susceptible to problems 
within cold chain transportation. This is represented by 16% lower vaccination coverage for 
DTP8 in countries with poor infrastructure and results in higher prevalence of disease. Using 
TTCF as a model we demonstrate that ensilication could be an ideal solution to overcome the 
challenges of biopharmaceutical ‘cold-chain’ transportation. 
We have previously described the retention of TTCF protein structure via ensilication at 
primary and tertiary level, including heat treated material, using biochemical methods 1. In the 
  
present study, we looked at two opposite experimental resolutions. Time resolved (in situ) 
SAXS was employed to assess tailor fitting of TTCF in silica. This is a powerful tool that can 
assess morphology of proteins and particles formed at nanometre scale over time. It provides 
the average shape and size of (in situ) particle growth using the radius of gyration (Rg) and 
allows for fitting of mathematical models to elucidate protein-silica particle formation 14,17. 
This could observe and possibly confirm tailored silica coating of TTCF at molecular level. On 
the other side of the spectrum, in vivo immunisation experiments could confirm feasibility of 
the end stage application for our methodology creating an opportunity to solve real-world 
challenges. 
Initial assessment of the protein scattering data confirmed a monodisperse solution of native 
TTCF (Supplementary S1, S2). Calculated parameters elucidate TTCF to be a prolate ellipsoid. 
The two independent SAXS experiments performed were intended to provide resolution of the 
onset and longer evolution of TTCF ensilication.  
 
Figure 1. SAXS scattering of continuous flow TTCF ensilication. (A) 3D plot of the first 120 seconds during the ensilication of TTCF. 
Observed is the development of silica particle growth upon onset of polymerisation. (B) Stacked plot of scattering for multiple time points 
during the experiment. Scattering scaled 1 log for each chosen time point. Red, green and blue fittings use a power law + ellipsoid, power law 
+ ellipsoid + mass fractal and broad peak + mass fractal model respectively (C) Batch analysis data fit results of acquired SAXS signal.  Cut-
off length (Å) = static length of silica particles coating TTCF, χ2 = residuals of fit for stage I fit model (Supplementary). 
 
  
The use of a flow-cell setup (figure S5) with sample agitation (Diamond Light Source, i22) 
allowed continuous measurement of the onset of TTCF ensilication. The q-range (figure 1, A) 
at 0.008≤q≤0.35 Å-1 displayed the rapid development of protein-silica particles after addition 
of hydrolysed TEOS. There is a change in scattering (figure 1, B) that is observed at high q 
(0.20≤q≤0.35 Å-1) and there are fluctuations in the low q-range (0.008≤q≤0.04 Å-1). The high 
q signal appears immediately after the hydrolysed TEOS is added which complements with 
other studies18 and indicates silica condensation induced by the presence of charged residues 
of the protein19. This is indicative of silica coating of TTCF via ensilication and after 
approximately 40 seconds the protein signal has shifted towards the low q range therefore 
providing evidence of particle growth caused by ensilication. Supporting this observation is 
the fractal structure formed at high q. After 60 seconds protein scattering gradually decreases 
and an amorphous peak is formed, situated around the identical q where the apex of native 
TTCF is present. 
 
Figure 2. SAXS scattering of TTCF ensilication over time. (A) 3D plot of the 60 minutes during the ensilication of TTCF. Observed is the 
development of silica particle growth. (B) Stacked plot of scattering for multiple time points during the experiment. Scattering scaled for 
clarity with added fits. Truncated high q for clarity. Red, blue and orange fittings use a power law + ellipsoid, broad peak + mass fractal, 
power law + mass fractal model respectively. (C) Batch analysis data on mass fractal fitting of acquired SAXS signal. Df = fractal dimension, 
r (Å) = fractal radius, cut-off length (Å) = static length of aggregating silica particles, χ2 = residuals of fit. 
 
  
Time resolved SAXS (ESRF, ID02) of non-agitated capillary setup (figure S6) TTCF 
ensilication displayed similar behaviour at 0.006≤q≤0.51 (Å-1) (figure 2, A). Here, the 
ensilication process was monitored after ex situ initiation of TTCF ensilication. After 
measurement was started, the amorphous peak at q-range of 0.03≤q≤0.08 (Å-1) (figure 1 and 2, 
B) was identified in both data sets. Additionally, the rapid increase in high-q signal is present 
here as well. Observed is the extension of this slope from 0.03≤q≤0.1 (Å-1) and indicated mass 
fractal growth of silica gel around TTCF ensilicated silica particles forming larger aggregates.  
There are visible differences in scattering between agitated and non-agitated sample that 
suggested this reaction to be diffusion controlled (figure S3). Fitting done on both data sets 
(figure 1&2, C) using various models indicate three stages during ensilication (figure 3).  
Stage I: Formation and growth of low q particle radii initiated at the onset of ensilication 
(figure 1 A, until ~40 sec). Here, ensilication is observed via the increase in ellipsoidal radii 
(polar, equatorial) over time, indicating silica forming around the protein.  
Stage II: Broad amorphous peak formation due to aggregation of silica.  
Stage III: Fractal growth of silica particles associated with aggregation which relates to 
increase in fractal dimension and cut-off length (figure 1, C). This is confirmed by the mass 
fractal dimension (Df ) during the longer evolution (figure 2, C) which provides an increase to 
 
Figure 3. Graphical representation of TTCF ensilication. Nucleation, induced via electrostatics, initiates ensilication at positive external 
residues (lysine, arginine, blue) present on the protein. Poly-condensation of SiOH4 results in silica coating of individual proteins (stage I, 
green) which triggers aggregation (stage II, blue). Vacuum filtration of the then turbid solution results in dried powder material containing 
protein loaded silica nanoparticles (FE-SEM at 15,000x magnification). 
 
 
  
Df  = 1.87 and has been shown to be indicative of fast silica growth and defines ensilication as 
a diffusion limited cluster aggregation (DLCA) type process20 (figure 3).  
Our findings are further supported by SAXS carried out a lower q-range (0.0008 to 0.05 
A-1) displaying large particle formation after silica addition (figure S4). Particle sizes 
increasing to a stable range of 2000 - 2200 Å (200-220 nm) are observed. This data suggests 
that once TTCF is coated with silica, it is prone to aggregate and form a stable complex. FE-
SEM imaging of the final dried material confirm these sizes (figure 3). Overall, the SAXS data 
provides evidence of a fast DLCA process where, once TTCF is coated, on average 2000 Å 
aggregates of protein-silica particles will form.  
To confirm our protective capacity in vivo, we immunised mice with TTCF or with 
TTCF after ensilication and obtained serum samples. Enzyme Linked Immuno-Sorbent Assay 
21 (ELISA) using native TTCF coated plates were employed to analyse the resultant immune 
response. As expected from previous studies22, we observed an early stage immune response 
in the mice injected with native TTCF and this immune response was matched when the mice 
were injected with TTCF which had been stored as ensilicated powder and released prior to 
immunisation (figure 4). 
 
Figure 4. Serum IgG response from mice immunised with TTCF after ensilication. Normalised absorbance values against monoclonal 
10G5 (RU: relative units). Sample groups consisted of 5 mice which were immunised with 5 µg of TTCF at the start of experiment and boosted 
at 28 days (arrow). Data are expressed as mean +/- SD (n=5). Statistical analysis was performed applying one-way ANOVA with post-hoc 
Tukey HSD test. Comparison vs native TCCF (ns = nonsignificant) or vs native TTCF heated to 80 °C to denature and inactivate ((* p ≤ 0.05, 
** 0.01 and *** 0.001,)  
The results confirmed the protective capacity of ensilication to maintain normal protein/epitope 
conformation at ambient temperature, as well as when the ensilicated material was heated at 
80 °C for 2 hours. The ensilicated material used during this study was stored in powdered form 
for 1 month at room temperature and then transported using commercially available means 
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without any specialised equipment. The ensilicated TTCF was protected from elevated 
temperature denaturation, as demonstrated by the lack of specific immune response when 
unprotected and heat-denatured TTCF was injected into mice (Figure 4 open circles). This 
demonstrates the ease and efficacy of use of our methodology. Additionally, flow cytometry 
analysis of day 42 (post-immunisation) splenocytes (figure S7) suggested ensilication of TTCF 
to have no influence on the measured immune response.  
We believe that this new methodology has given rise to another solution for 
biopharmaceutical stabilisation. In this study, we have confirmed ensilication using SAXS and 
demonstrated the protective capacity of ensilication via in vivo analysis, i.e. the 
immunogenicity for intact TTCF is maintained. All biopharmaceuticals have unique functions 
that require different environments for their operations. Therefore, for some, lyophilisation 
might work better as a means of stabilising and transporting the bioactive compounds. We 
propose that those which are not compatible with lyophilisation could be remediated via 
ensilication.  
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